THURSDAY, April 27, 2023 (HealthDay News) -- Many of top-selling drugs in Medicare in 2020 received low added-benefit ratings by the national health technology assessment (HTA) organizations in Canada, France, and Germany, according to a study published in the April 18 issue of the Journal of the American Medical Association. Alexander C. Egilman, from Brigham